Home
AbClon

AbClon Market Share Analysis for August 2026

앱클론 | 항체기술 플랫폼 개발사

Industry: N/A

Domainabclon.com

Year Founded--

Employees51 - 200

Annual Revenue$2M - $5M

AbClon

AbClon (including company regionals)

abclon.com

See more website traffic and engagement information

AbClon Revenue up to August 2026 is 2M - 5M

revenue generated by AbClon top domains

AbClon top domains revenue over 3 years

Revenue for AbClon top domains

abclon.com2M - 5M

See more with Sales Intelligence

Total visits to AbClon's top domains

Understand AbClon market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

abclon.com4.6K

See more with Sales Intelligence

Avg. visit duration in AbClon's top domains

Analyze AbClon engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

abclon.com00:00:13

See more with Sales Intelligence

Avg. pageviews on AbClon's top domains

See how AbClon keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

abclon.com2.40

See more with Sales Intelligence

AbClon top competitors by domain

Top similar sites in August 2026, ranked by their affinity

immunocore.comCompany NameImmunocoreEmployees201 - 500HQUnited Kingdom, AbingdonAnnual revenue$200M - $500MTotal visits12.6KHealth > Biotechnology and Pharmaceuticals

Top technologies used by AbClon

These are the website technologies, by industry, used by AbClon top domains

Advertising (1)

PubMatic

Audio Video Media (1)

Vimeo

eCommerce (1)

Cafe24 Nameserver

Mobile (1)

Meta Viewport

More Technologies

3

See all

News & Signals from AbClon

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAbClon Inc. is developing CAR-T cell therapy for solid cancer and target Claudin.AbClon said that it has partnered with the National Cancer Center (NCC) to develop a CAR-T (Chimeric Antigen Receptor-T) cell therapy for solid cancer and target Claudin (CLDN)-18.2 antigen.

NewsAbClon Inc. partnered with abtis GmbH on Aug 1st '21.Through the co-development project with Abtis, Abclon also plans to select antibodies developed by the NEST platform and make the best use of them.